Preliminary data from IR BioSciences Holdings, Inc. (OTC: IRBO)’s influenza vaccine adjuvant study being performed in conjunction with GenPhar Inc. revealed that its compound – Homspera - elevates host immune responsiveness above that induced by vaccine alone system.
The said data strongly indicate that Homspera may demonstrate adjuvant capabilities to vaccines for diseases such as pandemic avian influenza, seasonal influenza, and perhaps others for which vaccines exist or are under development.
Adjuvants are common additions to vaccine formulations, as they enable the vaccine to induce a strong immune reaction in vaccinated individuals, helping to ensure adequate immunological protection.Find more details from the full report.
Comment Preview